Table 3.
Association between the clinical variables of patients with metastatic prostate cancer (Stage D) and the OPG 950T/C genotype
| Osteoprotegerin 950T/C genotype | ||||
| CC | TC | TT | P3 | |
| n = 11 | n = 39 | n = 40 | ||
| Age1 | 74 (69–79) | 75 (68–81) | 72 (65–76) | 0.375 |
| Histological grade2 | ||||
| Low/Intermediate | 4 (9%) | 18 (39%) | 24 (52%) | 0.641 |
| High | 7 (16%) | 21 (48%) | 16 (36%) | |
| Clinical variables at diagnosis1 | ||||
| PSA (ng/ml) | 199 (66.4–296) | 257 (37.3–860) | 116 (30.0–267) | 0.270 |
| Hemoglobin (g/dl) | 12.8 (12.2–13.1) | 12.7 (11.1–13.7) | 13.2 (12.0–14.6) | 0.194 |
| ALP (IU/ml) | 189 (175–468) | 232 (177–360) | 201 (138–343) | 0.659 |
1Values represent the median (inter-quartile range).
2Values represent the number (%).
3Analysis of variance or chi-square test.
Abbreviations: PSA; prostate specific antigen, ALP, alkaline phosphatase.